NCT04407143

Brief Summary

Observational, retrospective data collection and prospective IgG analysis, and multicenter study. The main objective of the study is th description of the characteristics and evolution of patients with lung cancer who have acquired COVID-19 infection. For the identification of patients who contract COVID-19 infection, the IgG+ blood test by ELISA method will be used.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,980

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2020

Typical duration for all trials

Geographic Reach
1 country

68 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 15, 2020

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

May 25, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 29, 2020

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2022

Completed
Last Updated

February 9, 2026

Status Verified

June 1, 2022

Enrollment Period

2 years

First QC Date

May 25, 2020

Last Update Submit

February 5, 2026

Conditions

Keywords

IgGcoronavirusCOVID-19lung cancer

Outcome Measures

Primary Outcomes (1)

  • Description of the characteristics of patients

    Description of the characteristics and evolution of patients with lung cancer who have contracted COVID-19 infection.

    From the diagnosis of the COVID until the determination of the blood IgGs, up to 10 weeks

Secondary Outcomes (1)

  • Detection of antibodies (IgG) at 6 months after SARS-COV2 vaccines

    From the date of complete SARS-COV2 vaccination administration until 6 month

Study Arms (1)

lung cancer+COVID-19

Lung cancer patients infected by COVID-19

Diagnostic Test: IgG test

Interventions

IgG testDIAGNOSTIC_TEST

IgG+ blood test by ELISA method.

lung cancer+COVID-19

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who have not signed or do not wish to sign the informed consent for this study

You may qualify if:

  • Patients diagnosed with lung cancer at any stage of the disease
  • Age ≥ 18
  • Patients who have signed the informed consent for this study

You may not qualify if:

  • \. Patients who have not signed or do not wish to sign the informed consent for this study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (68)

Complejo Hospitalario de A Coruña

A Coruña, A Coruña, 15006, Spain

Location

Hospital General Universitario de Elche

Elche, Alicante, 03203, Spain

Location

Hospital Clínic de Barcelona

Barcelona, Barcelona, 08036, Spain

Location

ICO Hospitalet

L'Hospitalet de Llobregat, Barcelona, 08908, Spain

Location

Hospital Universitario de Burgos

Burgos, Burgos, Spain

Location

Hospital Universitario Reina Sofía

Córdoba, Córdoba, 14004, Spain

Location

Hospital Dr. Josep Trueta

Girona, Girona, 17007, Spain

Location

Hospital Universitario Insular de Gran canaria

Las Palmas de Gran Canaria, Gran Canaria, 35016, Spain

Location

Complejo Hospitalario de Jaén

Jaén, Jaén, 23007, Spain

Location

Hospital Universitario Fundación Jiménez Díaz

Madrid, Madrid, 28040, Spain

Location

Hospital Universitario 12 de Octubre

Madrid, Madrid, 28041, Spain

Location

Hospital Universitario La Paz

Madrid, Madrid, 28046, Spain

Location

Hospital Puerta de Hierro

Madrid, Madrid, 28222, Spain

Location

Clínica Universidad de Navarra

Madrid, Madrid, Spain

Location

Hospital de Sanchinarro

Madrid, Madrid, Spain

Location

Hospital Severo Ochoa

Madrid, Madrid, Spain

Location

Hospital Universitario Infanta Cristina

Madrid, Madrid, Spain

Location

Hospital Universitario de Torrejón

Torrejón, Madrid, Spain

Location

Hospital Universitario Son Llàtzer

Palma de Mallorca, Mallorca, 07198, Spain

Location

Hospital General Universitario de Málaga

Málaga, Málaga, 29010, Spain

Location

Complexo Hospitalario Universitario de Vigo

Vigo, Pontevedra, 36036, Spain

Location

Hospital Virgen del Rocío

Seville, Sevilla, 41013, Spain

Location

Hospital Universitario Nuestra Señora de Candelaria

Santa Cruz de Tenerife, Tenerife, Spain

Location

Hospital Universitari i Politécnic La Fe

Valencia, Valencia, 46009, Spain

Location

Hospital Clínico Universitario de Valencia

Valencia, Valencia, 46010, Spain

Location

Hospital General de Valencia

Valencia, Valencia, 46014, Spain

Location

Hospital Universitario Dr. Peset

Valencia, Valencia, Spain

Location

Hospital Clínico Universitario de Valladolid

Valladolid, Valladolid, 47003, Spain

Location

Hospital La Esperanza

A Coruña, Spain

Location

Hospital Universitario de Ferrol

A Coruña, Spain

Location

Hospital Virgen de los Lirios

Alicante, Spain

Location

Hospital Germans Trias i Pujol

Badalona, Spain

Location

Hospital de la Santa Creu i Sant Pau

Barcelona, Spain

Location

Hospital Universitari Dexeus

Barcelona, Spain

Location

Hospital Universitario Cruces

Bilbao, Spain

Location

Hospital Universitario Puerta del Mar

Cadiz, Spain

Location

Hospital Universitario Puerto Real

Cadiz, Spain

Location

Hospital Universitario San Pedro de Alcántara

Cáceres, Spain

Location

Hospital General La Mancha Centro

Ciudad Real, Spain

Location

Hospital Universitario de Vinalopó

Elche, Spain

Location

Hospital Universitario de Guadalajara

Guadalajara, Spain

Location

Complejo Asistencial Universitario de León

León, Spain

Location

Hospital universitari Arnau de Vilanova

Lleida, Spain

Location

Hospital San Pedro

Logroño, Spain

Location

Hospital Universitario Lucus Augusti

Lugo, Spain

Location

Hospital General Universitario Gregorio Marañón

Madrid, Spain

Location

Hospital Universitario de Móstoles

Madrid, Spain

Location

Hospital Universitario del Henares

Madrid, Spain

Location

Hospital Universitario Fundación Alcorcón

Madrid, Spain

Location

Hospital Universitario Infanta Leonor

Madrid, Spain

Location

Hospital Universitario Infanta Sofía

Madrid, Spain

Location

Hospital Universitario Príncipe de Asturias

Madrid, Spain

Location

Hospital Costa del Sol

Málaga, Spain

Location

Complejo Hospitalario Universitario de Ourense Santa María Nai

Ourense, Spain

Location

Hospital Universitario Son Espases

Palma de Mallorca, Spain

Location

Clínica Universidad de Navarra

Pamplona, Spain

Location

Complejo Hospitalario de Navarra

Pamplona, Spain

Location

Hospital Universitario Sant Joan de Reus

Reus, Spain

Location

Hospital Universitario de Salamanca

Salamanca, Spain

Location

Hospital Universitario de Canarias

Santa Cruz de Tenerife, Spain

Location

Hospital General de Segovia

Segovia, Spain

Location

Hospital Sant Pau i Santa Tecla

Tarragona, Spain

Location

Hospital Arnau de Vilanova

Valencia, Spain

Location

Hospital de Manises

Valencia, Spain

Location

Hospital General Universitario de Valencia

Valencia, Spain

Location

Hospital Lluís Alcanyís

Valencia, Spain

Location

Hospital Universitario Río Ortega

Valladolid, Spain

Location

Complejo Hospitalario Zamora

Zamora, Spain

Location

Related Publications (2)

  • Provencio M, Estival A, Franco F, Lopez-Vivanco G, Saigi M, Arasanz H, Diz P, Carcereny E, Garcia J, Aguado C, Mosquera J, Iruarrizaga E, Majem M, Bosch-Barrera J, Mielgo-Rubio X, Guirado M, Juan-Vidal O, Blasco A, Lucia Gozalvez C, Del Barrio A, De Portugal T, Lopez-Martin A, Serrano G, Campos B, Rubio J, Catot S, Esteban B, Marti-Ciriquian JL, Del Barco E, Calvo V; Spanish Lung Cancer Group (SLGC/GECP). Immunogenicity of COVID-19 vaccines in lung cancer patients. Lung Cancer. 2023 Oct;184:107323. doi: 10.1016/j.lungcan.2023.107323. Epub 2023 Aug 9.

  • Provencio M, Rodriguez-Abreu D, Ortega AL, Serrano G, Aguado C, Franco F, Gutierrez V, Lopez Vivanco G, Guirado M, Benitez G, Estival A, Calvo V, Jimenez B, Arasanz H, Coves J, Majem M, Massuti B, Vazquez S, Juan-Vidal O, Collazo-Lorduy A, Gozalvez CL, Del Barco E, Rosero A, Bosch-Barrerra J, Moreno MA, Mielgo-Rubio X, Villa JC, Lopez-Martin A, Cordoba JF, de Asis Aparisi F, Zafra M, Mosquera J, Perez Altozano J, Nadal E, Catot S, Balsalobre J, de Portugal T, Martin P, Cuesta de Juan S, Cobo M. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Transl Lung Cancer Res. 2022 Jan;11(1):53-63. doi: 10.21037/tlcr-21-504.

Related Links

MeSH Terms

Conditions

Lung NeoplasmsCoronavirus InfectionsCOVID-19

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsVirus DiseasesInfectionsPneumonia, ViralPneumoniaRespiratory Tract Infections

Study Officials

  • Mariano Provencio, MD

    Hospital Puerta de Hierro de Majadahonda de Madrid

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 25, 2020

First Posted

May 29, 2020

Study Start

April 15, 2020

Primary Completion

April 30, 2022

Study Completion

May 30, 2022

Last Updated

February 9, 2026

Record last verified: 2022-06

Data Sharing

IPD Sharing
Will not share

Locations